CCR2 and metabolic dysfunction-associated steatohepatitis: Similarly, the chemokine C-C chemokine receptor 2/5 (CCR2/CCR5) inhibitor (cenicriviroc) suppresses recruitment of monocytes and activation of HSCs, and is currently being evaluated in a phase 3 clinical study (NCT03028740) in NASH patients with liver fibrosis.